儿童肾母细胞瘤术前全身静脉化疗与经导管动脉栓塞化疗临床疗效对比研究

【目的】对比分析术前全身静脉化疗和经导管动脉栓塞化疗对儿童肾母细胞瘤的疗效。【方法】回顾性选取本院2010年1月至2019年12月收治的肾母细胞瘤患儿作为研究对象,其中48例通过经导管动脉栓塞方式进行术前化疗(观察组),33例以全身静脉给药方式进行化疗(对照组)。观察两组的肿瘤减积率、肿瘤坏死率、包膜完整率、术前化疗总体有效率、肿瘤全切率、2年无瘤生存率和不良反应。【结果】观察组的肿瘤减积率、肿瘤坏死率、包膜完整率、术前化疗总体有效率和肿瘤全切率均高于对照组,不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。对照组的2年无瘤生存率(94%)高于观察组(88%),但是差异无统计学意义(P>0.05)。【结论】儿童肾母细胞瘤术前应用经导管动脉栓塞化疗与全身静脉化疗相比,更利于手术切除,疗效更高,不良反应更少,但是在2年无瘤生存率上未展现更好的优势,还需要进一步扩大样本量和随访时间进行临床研究。

Comparative Study of Preoperative Systemic Intravenous Chemotherapy and Transcatheter Arterial Embolization Chemotherapy in Children with Nephroblastoma

[Objective]To comnpare and analyze the ele of preoperaive systemie venous chemotherapy and tran-scatheter arterial embolization chemotherapy on nephroblastoma in children.[Methods]Children with nephroblastoma ad-mitted to our hospital from January 2010 to December 2019 were selected retrospectively as the study obiects.Among them,48 cases rceived preoperative chemotherapy by transcranial arterial embolization as the observation group.and 33 cases reeived systenic intravenous chemotherapy as the control group.T he tumor volume reduction rate.tumor necrosis rate,capsule integrity rate,overall ffective rate of preoperative chemotherapy,total tumor resection rate,2-year tumor-free survival rate and adverse reactions were observed and compared in the two groups.[Results]Tumor volume reduction rate,tumor necrosis rate,capsule integrity rate,overall efective rate of preoperative chemotherapy and total tumor resee-tion Tate were all higher in the observation group than in the control group.and the incidence of adverse reactions was lower than that in the control group.with statistically significant differences(P<0.05).The 2-year tumor free survival rate in the control group(94%)was higher than that in the observation group(88%),but the dfference was not staisi-cally significant(P<0.05).[Conclusion]Compared to systemic intravenous chemotherapy.preoperative transcranial ar-terial embolization is more beneficial to surgical resection,with higher eficaey and fewer adverse reactions in children with nephroblastoma.However,it does not show a better advantage in 2 year tumor-free survival rate.8s0 it is necessary to further expand the sample size and fllw up time for elinical study.